If cross-presentation of tumor peptides during ACT enhanced endogenous CD8+ T cell responses against targets other than LCMV GP33–41, then broadening the spectrum of antitumor killing may represent an important mechanism to prolong tumor regression. Here, CD8A is linked to neoplasm.